Lupus Clinical Trials
Here are the 6 most popular medical studies for lupus
Behavioural Intervention
Vagus nerve stimulation for Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune, inflammatory disease and musculoskeletal pain is one of the most common symptoms. This study will investigate whether transcutaneous stimulation of the vagus nerve will decrease lupus musculoskeletal pain. This study will additionally investigate the biologic effects of vagus nerve stimulation on inflammation. It will be the first clinical study using one of the body's own pathways of modulating the immune system and inflammatory response, the cholinergic anti-inflammatory pathway, in SLE.
Mucolytic Agent
N-acetylcysteine for Lupus
This trial is a phase II study to test the safety and efficacy of N-acetyl cysteine (NAC) in treating systemic lupus erythematosus (SLE). SLE is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. This study will have two groups of 105 subjects each, with one group continuing the tolerated dosage of NAC and the other group switched to placebo capsules. The study will last 13 months with seven study visits per subject. Each subject will donate approximately 100 ml of blood
Popular filter options for lupus trials
Anti-dsDNA Positive Clinical Trials
View 12 anti-dsDNA positive medical studies.
Monoclonal Antibodies
Obinutuzumab for Lupus
This trial will compare the effects of a new drug, obinutuzumab, to a placebo in people with active SLE. The trial will be double-blind, meaning neither the participants nor the researchers will know who is receiving the real drug or the placebo.
Phase 3 Lupus Clinical Trials
View 91 phase 3 lupus medical studies.
Monoclonal Antibodies
Litifilimab for Systemic Lupus Erythematosus
This trial is testing a new drug for Lupus called BIIB059. The objective is to see if it is more effective than a placebo in reducing disease activity. There are also secondary objectives to see if it has early onset of efficacy, if it works on specific parts of the body, and if it has other benefits. Finally, they will assess the safety and tolerability of the drug.
Monoclonal Antibodies
Litifilimab for Lupus
This trial is testing a new drug for Lupus called BIIB059. The goal is to see if it is effective in reducing disease activity, and if it has any other benefits compared to placebo. There are many secondary objectives to this study, including assessing the safety and immunogenicity of the drug.
Lupus Clinical Trials With No Placebo
View 91 lupus medical studies that do not have a placebo group.
Corticosteroid
Glucocorticoids for Lupus
This trial is investigating how GCs affect the immune system in people with SLE in order to develop new and better drugs for treating the disease. Eligible participants will undergo screening tests and then have a methylprednisolone infusion. Blood will be collected at various times afterwards and participants will be contacted afterwards to discuss any health problems.
View More Lupus Trials
See another 60 medical studies focused on lupus.
Frequently Asked Questions
Introduction to lupus
What are the top hospitals conducting lupus research?
Lupus, an autoimmune disease that affects millions of people worldwide, has sparked a surge in clinical trials aimed at finding new treatments and interventions. In Oklahoma City, the Oklahoma Medical Research Foundation leads the charge with seven ongoing lupus trials. This innovative facility is dedicated to unraveling the mysteries of this complex condition and paving the way for improved management options. SUNY Upstate Medical University in Syracuse also plays a vital role in lupus research, currently conducting six active clinical trials. Researchers here are committed to discovering breakthroughs that can alleviate the burden of this chronic illness on patients' lives.
In Dallas, the Metroplex Clinical Research Center is actively involved in five lupus trials, striving to uncover better ways to diagnose and treat this challenging condition. Meanwhile, at the Medical University of South carolina in Charleston, researchers are working diligently on five ongoing clinical studies focused on lupus intervention and management strategies.
Finally, NYU Langone Health joins these esteemed institutions with four active lupus trials taking place within its walls. Located in New york City—a hub for medical innovation—NYU Langone Health is part of a vibrant community committed to advancing our understanding of autoimmune diseases like lupus.
These hospitals stand as beacons of hope for individuals living with lupus across the United States and beyond. Through their dedication and tireless efforts, they strive not only to improve treatment options but also offer promising avenues towards a future where individuals affected by this debilitating disease can lead fuller lives.
Which are the best cities for lupus clinical trials?
When it comes to lupus clinical trials, several cities emerge as leaders in research and innovation. New york City boasts 33 active trials, focusing on treatments like Hydroxychloroquine (HCQ), Deucravacitinib, and CC-97540 administration. Miami, Florida follows closely with 29 ongoing studies exploring Nipocalimab, ALPN-101, and GLPG3667 as potential therapies. Houston, Texas is also a hub for lupus clinical trials with 25 active studies investigating treatments such as ALPN-101 and Cenerimod. These cities offer individuals living with lupus access to cutting-edge research that may lead to improved outcomes and better management of this autoimmune disease.
Which are the top treatments for lupus being explored in clinical trials?
Lupus, a complex autoimmune disease, is being targeted by several noteworthy treatments currently undergoing clinical trials. At the forefront of research is belimumab, an established medication that has shown promising results and continues to be explored in ongoing studies. Another contender is baricitinib, a newer drug with potential benefits for lupus patients. Additionally, voclosporin—an immunosuppressant—has also emerged as a treatment option worthy of investigation. These innovative therapies offer hope for individuals living with lupus and may pave the way for improved management of this challenging condition.
What are the most recent clinical trials for lupus?
Exciting advancements in lupus research offer hope for improved treatment options. Recent clinical trials have explored various therapeutic approaches to tackle this complex autoimmune disease. In one study, BMS-986326 Dose 1 IV was investigated in Phase 1, showing promise as a potential treatment option. Another trial focused on Imvotamab (Dose Escalation), aiming to evaluate its efficacy and safety profile in lupus patients. Additionally, the effectiveness of the Herpes Zoster Subunit (HZ/su) Vaccine is being examined in Phase 4 to provide valuable insights into its use for individuals with lupus. Furthermore, Study 3 examines Upadacitinib Dose A's impact on lupus patients and holds potential as an innovative therapy option. These ongoing efforts signal progress in understanding and addressing lupus, offering renewed hope for those affected by this condition.
What lupus clinical trials were recently completed?
Recently completed clinical trials in the field of lupus have shown promising advancements in our understanding and treatment of this complex autoimmune disease. Notably, a trial sponsored by GlaxoSmithKline investigating Anifrolumab reached its completion, offering potential new options for patients. Additionally, a study led by Pfizer explored the efficacy of PF-04965842 as a therapeutic approach for lupus patients. These recent milestones highlight the ongoing efforts to improve outcomes and quality of life for individuals battling with lupus.